Asarina Pharma issues new shares to Ergomed plc
(Stockholm, 20 February, 2020) Asarina Pharma AB (publ) (“Asarina Pharma” or the “Company”) today announces that it will, pursuant to the authorisation granted by the Annual General Meeting on 21 January 2020, issue 301,724 new shares to Ergomed plc (“Ergomed”), the CRO carrying out Asarina Pharma’s phase IIb PMDD study.The share issue is triggered by the achievement of a milestone in the PMDD study, and it represents 1.6% of the current share capital in Asarina Pharma. The current payment to Ergomed amounts to SEK 8,387,927.20 and the number of shares has been determined at the market